Verastem (VSTM)
(Delayed Data from NSDQ)
$2.92 USD
+0.06 (2.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $2.93 +0.01 (0.34%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.92 USD
+0.06 (2.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $2.93 +0.01 (0.34%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Verastem (VSTM) delivered earnings and revenue surprises of 16.67% and -1.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates
by Zacks Equity Research
Key highlights of the past week include label expansion of drugs, licensing deals and more.
Verastem's (VSTM) Copiktra Gets Orphan Drug Designation
by Zacks Equity Research
Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.
Verastem (VSTM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Verastem (VSTM) delivered earnings and revenue surprises of 2.04% and 41.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Verastem Up on Positive Data From Early-Stage Copiktra Study
by Zacks Equity Research
Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
by Zacks Equity Research
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.
Verastem (VSTM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Verastem (VSTM) delivered earnings and revenue surprises of -10.87% and -41.16%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Verastem (VSTM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Verastem (VSTM) delivered earnings and revenue surprises of 31.48% and -78.25%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Verastem (VSTM) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (VSTM) Outperforming Other Medical Stocks This Year?
Infinity (INFI) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Infinity (INFI) beats earnings estimates in the third quarter of 2018. The company revised its outlook for 2018 and expects net loss for 2018 to be $10-$20 million, down from its previous expectation of $35-$45 million.
What's in Store for Verastem (VSTM) This Earnings Season?
by Zacks Equity Research
On Verastem's (VSTM) third-quarter conference call, investor focus will be on the company's launch and reimbursement plans for its newly approved leukemia drug Copiktra.
Verastem Out-Licenses China Rights to Cancer Drug Copiktra
by Zacks Equity Research
Verastem (VSTM) out-licenses rights to develop/commercialize its newly approved cancer drug Copiktra to the Chinese entity, CSPC Pharmaceutical.
Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
Verastem (VSTM) in Focus: Stock Moves 8% Higher
by Zacks Equity Research
Shares of Verastem (VSTM) rose nearly 8% yesterday.
Infinity (INFI) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Infinity (INFI) incurs narrower-than-expected Loss in Q4 and expects to report data from the monotherapy expansion and combination dose escalation components of its pipeline candidate IPI-549.
Options Traders Expect Huge Moves in Verastem (VSTM) Stock
by Zacks Equity Research
Surging level of implied volatility makes Verastem (VSTM) stock lucrative to the investors.
Infinity (INFI) Q3 Loss Narrower than Expected, View Intact
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) Q3 loss was narrower than estimates and the year-ago quarter loss.
Implied Volatility Surging for Verastem (VSTM) Stock Options
by Zacks Equity Research
Verastem (VSTM) needs Investors to pay close attention to the stock based on moves in the options market lately.
Verastem (VSTM) Shows Strength: Stock Adds 42% in Session
by Zacks Equity Research
Verastem, Inc. (VSTM) shares jumped almost 42% in the last trading session.